A prospective, open-label, phase II, multi-center study of the safety, tolerability and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted (CAIV-T) in healthy children, aged 6 to 17 years.

Trial Profile

A prospective, open-label, phase II, multi-center study of the safety, tolerability and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted (CAIV-T) in healthy children, aged 6 to 17 years.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 31 Oct 2006 Status change
    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top